Special Issue "Radiopharmaceutical Chemistry and Radiotherapy"
Deadline for manuscript submissions: 30 January 2020
Dr. Thaddeus J. Wadas
Department of Cancer Biology, Wake Forest University Health Sciences, Winston-Salem, NC 27157, USA
Website | E-Mail
Interests: radiotherapy; positron emission tomography; molecular imaging; zirconium-89; actinium-225; pancreatic cancer; prostate cancer; breast cancer; sarcoma; lung cancer
This Special Issue is related to recent developments in the field of radiopharmaceutical chemistry with a special emphasis on radiotherapy.
As part of their clinical care, physicians recommend radiation therapy as primary, neo-adjuvant, adjuvant, or palliative treatments to more than half of all cancer patients. Radiation therapy uses the intense energy associated with ionizing radiation to destroy cancerous cells. This radiation can be administered from an external source, through brachytherapy, or by using the systemic circulation to deliver therapeutic radiopharmaceuticals, which are designed to exploit dysregulated physiological processes and protein overexpression that cancer cells use to survive. Recently, several systemic radiotherapies have demonstrated efficacy in the clinic or in clinical trials; these successes have renewed interest in their development and integration into precision medicine strategies for cancer care. This Special Issue seeks to highlight the creative collaborations among researchers in the physical, biological, and health sciences that are conducting innovative preclinical or clinical radiotherapy research. All researchers working in the field are cordially invited to contribute original research papers or reviews to this Special Issue of Molecules.
Dr. Thaddeus J. Wadas
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Production and radiochemistry
- Auger therapy
- Beta minus (β-) therapy
- Alpha particle (α2+) therapy
- Theranostic pairs
- Image guided radiotherapy
- Radiotherapy clinical trials
- Regulatory aspects relating to radiotherapy
- Radionuclide generators